Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04112667
Other study ID # 1R01EY029595
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date October 7, 2019
Est. completion date August 31, 2024

Study information

Verified date June 2023
Source University of Alabama at Birmingham
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Delayed rod-mediated dark adaptation (RMDA), or delayed recovery of vision in a dark environment, is a functional biomarker (i.e., risk factor) for early age-related macular degeneration (AMD). This research plan is designed to elucidate the structural (anatomical) basis of this visual deficit using cellular- and subcellular level imaging of the retina and its supporting tissues in living people. An accurate map and timeline of structure-function relationships in persons tested for night vision will result in functionally validated structural endpoints for early AMD trials, as well as define major biologic effects for development into future treatments.


Description:

The Alabama Study on Early Age-Related Macular Degeneration 2 (ALSTAR2) is a prospective cohort study with baseline measurements that are repeated at follow-up 3 years later. The baseline and 3 year follow-up visits will each consist of 2 visits for a total of 4 visits. Study assessments are listed below. All are collected at two visits at both baseline and follow-up for 4 visits total (blood collection for DNA analysis at baseline only). For some functional tests (photopic and mesonic acuity, photopic and mesonic contrast sensitivity), each eye will be tested separately. For other functional tests (dark-adapted two-color perimetry, light-adapted cone-mediate perimetry, rod-mediated dark adaptation), only one eye will be tested, which will be designated by the study eye. Tropicamide 1% and phenylephrine hydrochloride 2.5% are used to dilate pupils (diameter of ≥ 6 mm) as needed for specific parts of the protocol. After completing the baseline visits, participants will receive an annual phone call from the study coordinator so that contact information can be updated. Participants will receive an annual newsletter containing study related information (this will be submitted to the IRB for approval). Study Assessments: 1. Rod-mediated dark adaptation (RMDA), the ability to recover light sensitivity after exposure to a bright light. 2. Dark-adapted two-color microperimetry, a measure of light sensitivity for lights of two different colors. 3. Photopic and mesopic acuity in central vision, as measured by letter charts.. 4. Photopic and mesopic contrast sensitivity in central vision, as measured by letter charts.. 5. Multimodal ocular imaging on both eyes, which consists of the following: color fundus photography, spectral domain optical coherence tomography (SDOCT), blue fundus autofluorescence (standard and quantitative), OCT-angiography (OCT-A). 6. Blood draw for the analysis of C-reactive protein, high-density lipoprotein, carotenoid level, DNA extraction, and examination of the presence of genetic risk associated with age-related macular degeneration (AMD). 7. Questionnaires: Demographics, medical co-morbidities, cognitive status screen, medication use, alcohol use, smoking, self-reported visual difficulty in the visual activities of daily living The Young normal group will only complete: 1. Rod-mediated dark adaptation (RMDA), the ability to recover light sensitivity after exposure to a bright light. 2. Dark-adapted two-color microperimetry, a measure of light sensitivity for lights of two different colors. 3. . Photopic and mesopic acuity in central vision, as measured by letter charts.. 4. Photopic and mesopic contrast sensitivity in central vision, as measured by letter charts.. 5. Multimodal ocular imaging on both eyes, which consists of the following: color fundus photography, spectral domain optical coherence tomography (SDOCT), blue fundus autofluorescence (standard and quantitative),OCT-angiography (OCT-A).d and quantitative), OCT-angiography.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 556
Est. completion date August 31, 2024
Est. primary completion date August 31, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: For those in Normal Macular Health or Early AMD: aged = 60 years; either have normal macular health in both eyes at baseline or have early AMD in one eye For Young Normals: aged 20-30 years old; normal macular health in both eyes. Exclusion Criteria: Exclusion for those in normal macular health are: - ANY EYE CONDITION OR DISEASE IN EITHER EITHER (OTHER THAN EARLY CATARACT) THAT CAN IMPAIR VISION INCLUDING: - diabetic retinopathy - glaucoma - ocular hypertension - history of retinal diseases (e.g., retinal vein occlusion, retinal degenerations) - optic neuritis - corneal disease - previous ocular trauma or surgery - REFRACTIVE ERROR >- 6 DIOPTERS - NEUROLOGICAL CONDITIONS THAT CAN IMPAIR VISION OR JUDGEMENT INCLUDING: - multiple sclerosis - Parkinson disease - stroke - Alzheimer disease - seizure disorders - brain tumor - traumatic brain injury - PSYCHIATRIC DISORDERS THAT COULD IMPAIR THE ABILITY: - to follow simple directions - answer questions about health and functioning - or to provide informed consent - DIABETES - ANY MEDICAL CONDITION THAT CAUSES SIGNIFICANT FRALITY OR IS BELIEVED TO BE TERMINAL. Exclusion criteria for the early AMD group: These are identical to those described above, except that it is acceptable for participants to have early AMD (AREDS 2-4) in one eye and be AREDS grade 1 or any stage of AMD in the fellow eye. Exclusion for Young Normals: - ANY EYE CONDITION OR DISEASE IN EITHER EYE (OTHER THAN EARLY CATARACT) THAT CAN IMPAIR VISION INCLUDING: - diabetic retinopathy - glaucoma - ocular hypertension - history of retinal diseases (e.g., retinal vein occlusion, retinal degenerations) - optic neuritis, corneal disease - previous ocular trauma or surgery - RERACTIVE ERROR >=6 DIOPTORS - NEUROLOGICAL CONDITIONS THAT CAN IMPAIR VISION OR JUDGEMENT INCLUDING: - multiple sclerosis - Parkinson disease - stroke - Alzheimer disease - seizure disorders - brain tumor - traumatic brain injury - PSYCHIATRIC DISORDERS THAT COULD IMPAIR THE ABILITY TO: - follow simple directions - answer questions about health and functioning - or to provide informed consent - DIABETES - ANY MEDICAL CONDITION THAT CAUSES SIGNIFICANT FRAILTY OR IS BELIEVED TO BE TERMINAL.

Study Design


Intervention

Other:
Normal Macular Health
This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
Early Macular Degeneration
This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.
Young Normals
This group of participants will have function assessed using rod- and cone-mediated tests (rod-mediated dark adaptation, 2 color dark adapted perimetry, cone-mediated perimetry, photopic and mesopic acuity, photopic and mesopic contrast sensitivity). Age-related macular degeneration status will be determined by multi-modal imaging.

Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama

Sponsors (1)

Lead Sponsor Collaborator
Cynthia Owsley

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rod-mediated dark adaptation Time required to recover light sensitivity after exposure to bright light Measured at baseline enrollment
Primary Rod-mediated dark adaptation Time required to recover light sensitivity after exposure to bright light Measured at 3 years after baseline enrollment
Primary incident age-related macular degeneration (AMD) or progression of AMD using multimodal imaging development of AMD or progression of AMD at the 3 year follow up visit Measured at baseline enrollment
Primary incident age-related macular degeneration (AMD) or progression of AMD using multimodal imaging development of AMD or progression of AMD at the 3 year follow up visit Measured at 3 years after baseline enrollment
Secondary Light sensitivity as measured by microperimetry and perimetry Amount of light needed to detect a small target object Measured at baseline enrollment
Secondary Light sensitivity as measured by microperimetry and perimetry Amount of light needed to detect a small target object Measured at 3 years after baseline enrollment
Secondary Photopic and mesopic acuity Visual acuity under day time and twilight conditions Measured at baseline enrollment
Secondary Photopic and mesopic acuity Visual acuity under day time and twilight conditions Measured at 3 years after baseline enrollment
Secondary Photopic and mesopic contrast sensitivity Amount of contrast needed to recognize a letter under day time and twilight conditions Measured at baseline enrollment
Secondary Photopic and mesopic contrast sensitivity Amount of contrast needed to recognize a letter under day time and twilight conditions Measured at 3 years after baseline enrollment
See also
  Status Clinical Trial Phase
Completed NCT05433233 - Effects of Lifestyle Walking on Blood Pressure in Older Adults With Hypertension N/A
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Completed NCT05293730 - Trial of the Impact of the Electronic Frailty Integrated With Social Needs N/A
Recruiting NCT03932162 - Gene Expression Changes In Young and Geriatric Skin Early Phase 1
Completed NCT04064528 - Effects of Age on Amino Acid Delivery to Tendon N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT06029920 - Influence of Overground Walking on Biomarkers, Cognitive Function, and Quality of Life in Elderly With Mild Cognitive Impairment N/A
Recruiting NCT05566938 - Study to Design a Precision Nutrition Strategy at a Group Level in the Elderly N/A
Recruiting NCT05543980 - Leg Heat Therapy in Elderly Individuals Phase 2
Completed NCT04894929 - Comprehensive Geriatric Assessment in the Monitoring of Functional Improvement N/A
Not yet recruiting NCT06071130 - Emotion, Aging, and Decision Making N/A
Enrolling by invitation NCT04641663 - Multi-target Dietary Supplement Tolerability in an Aging Population (MTDSST) N/A
Completed NCT04088006 - The Evaluation of Efficacy and Safety of Hyaluronic Acid Injection on Skin Moisturization and Elasticity N/A
Completed NCT03695081 - Patient Pathway Pharmacist - Optimal Drug-related Care N/A
Recruiting NCT05424263 - Acetate and Age-associated Arterial Dysfunction Phase 2
Completed NCT05601713 - Mitigating Heat-induced Physiological Strain and Discomfort in Older Adults Via Lower Limb Immersion and Neck Cooling N/A
Completed NCT04551339 - Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19 N/A
Recruiting NCT04997577 - Speech Perception and High Cognitive Demand N/A
Completed NCT05922475 - Efficacy of Pre-sleep or Post-exercise Protein During 12 Weeks of Resistance Exercise Training N/A
Completed NCT04015479 - Peanut Protein Supplementation to Augment Muscle Growth and Improve Markers of Muscle Quality and Health in Older Adults N/A